Our reference: CLINPR 100015
P-authorquery-v11
AUTHOR QUERY FORM Journal: CLINPR
Please e-mail your responses and any corrections to:
Article Number: 100015
Dear Author, Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours. For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions. We were unable to process your file(s) fully electronically and have proceeded by Scanning (parts of) your article
Rekeying (parts of) your article
Scanning the artwork
Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the ‘Q’ link to go to the location in the proof.
Location in article
Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
Q1
Please confirm that given names and surnames have been identified correctly and are presented in the desired order, and please carefully verify the spelling of all authors’ names.
Q2
The author names have been tagged as given names and surnames (surnames are highlighted in teal color). Please confirm if they have been identified correctly.
Q3
Please confirm that the provided email
[email protected] is the correct address for official communication, else provide an alternate e-mail address to replace the existing one, because private email addresses should not be used in articles as the address for communication.
Q4
Research Highlights should consist of only 125 characters per bullet point, including spaces. However, the research highlights provided for this item exceed the maximum requirement. Kindly provide the necessary corrections. For more information, please see Guide for Authors.
Q5
This sentence has been reworded for clarity. Please check and confirm that the meaning is still correct.
Q6
Uncited reference: This section comprises references that occur in the reference list but not in the body of the text. Please position each reference in the text or, alternatively, delete it. Thank you.
Q7
Journal style requires that in references, if there are six authors or fewer, all their names should be provided but if there are seven or more authors, the names of the first six authors should be provided followed by "et al." Please modify all applicable references. Please check this box if you have no corrections to make to the PDF file.
□ Page 1 of 2
Our reference: CLINPR 100015
P-authorquery-v11
Thank you for your assistance.
Page 2 of 2
CLINPR-100015; No of Pages 1 Clinical Infection in Practice xxx (xxxx) xxx
Contents lists available at ScienceDirect
Clinical Infection in Practice journal homepage: https://www.journals.elsevier.com/clinpr
Highlights Clinical Infection in Practice xxx (2020) xxx – xxx
Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy
4
Felix Bongomin a,b, Akaninyene Otu a,c,⁎, Chris Harris a, Philip Foden d, Chris Kosmidis a, David W. Denning a
5
F
2 3
O
1
a
7
b
8
c
9
d
10 11 12 13 14 15 16
• Relapse is problematic in chronic pulmonary aspergillosis (CPA) following discontinuation of triazole maintenance therapy • We defined relapse as a deterioration in two of the following parameters: clinical, radiological, serological or sputum microbiological markers of CPA activity. • Patients with bilateral chronic pulmonary aspergillosis are three times more likely to relapse after treatment discontinuation compared to those with unilateral disease. • A longer duration of treatment, e.g. 24 months, may be associated with a lower rate of relapse in extensive CPA, whereas more limited disease may respond to shorter courses.
U
N
C
O
R R
E
C
T
E
D
P
The National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust Department of Medical Microbiology & Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda Department of Internal Medicine, College of Medical Sciences, University of Calabar, Nigeria Department of Medical Statistics, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
R O
6
https://doi.org/10.1016/j.clinpr.2020.100015 2590-1702/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015
Q4
CLINPR-100015; No of Pages 5 Clinical Infection in Practice xxx (xxxx) xxx
Contents lists available at ScienceDirect
Clinical Infection in Practice journal homepage: https://www.journals.elsevier.com/clinpr
F
4 5 6 7 8
a
9
a r t i c l e
10 11 12 13 14 19 18 17 16 15 36 37 38 39
Article history: Received 28 May 2019 Received in revised form 6 November 2019 Accepted 15 December 2019 Available online xxxx
The National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust Department of Medical Microbiology & Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda Department of Internal Medicine, College of Medical Sciences, University of Calabar, Nigeria d Department of Medical Statistics, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK b
i n f o
R O
c
O
Felix Bongomin a,b, Akaninyene Otu a,c,⁎, Chris Harris a, Philip Foden d, Chris Kosmidis a, David W. Denning a
a b s t r a c t
P
Q23Q1
Objectives: We aimed to identify the frequency and risk factors for disease relapse following cessation of antifungal therapy in CPA. Methods: This retrospective audit at the National Aspergillosis Centre, Manchester, UK assessed outcomes for patients with CPA who had received antifungal treatment and for whom therapy was discontinued for at least one month between August 2009 and May 2017. We defined relapse as a deterioration in two of the following parameters: clinical, radiological, serological or sputum microbiological markers of CPA activity. Results: Therapy was discontinued in 102 patients. Age distribution was 63.7 ± 11.5 years. Therapy was recommenced in 43 (42%) patients of whom 21 met our definition of relapse — 31% of those with bilateral and 11% of those with unilateral disease. Patients with bilateral disease and those with ≥ 1 aspergillomas were more likely to relapse on univariate analysis. In a multivariable logistic regression analysis, bilateral disease was the only independent risk factor for relapse (OR: 3.0; 95% CI: 1.0–8.8; p = .044). Conclusions: Bilateral CPA is a risk factor for relapse after treatment discontinuation. A longer duration of treatment may be associated with a lower rate of relapse in extensive CPA, whereas more limited disease may respond to shorter courses. © 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
D
2
Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy
Keywords: Chronic pulmonary aspergillosis Relapse Risk factors
E
C
T
E
1
35
R
43 41 40 42
1. Introduction
45 46
Chronic pulmonary aspergillosis (CPA) refers to a spectrum of syndromes characterised by slowly progressive destruction of lung parenchyma with the creation of new cavities or expansion of existing ones. CPA manifests with prominent respiratory and/or systemic symptoms and is associated with significant morbidity and mortality [1]. Long-term oral triazole therapy is the mainstay of treatment for most patients, with the exception of some with localised disease who may be offered surgery [1,2]. However, acquired resistance during therapy, drug-related side effects and disease recurrence after cessation of treatment are the major management challenges [3–6]. Recurrence is thought to be common in CPA following discontinuation of triazole maintenance therapy. However, very few studies, often involving small numbers of patients, have investigated this. Clinical, mycological, serological and radiological parameters, all or in combination have been used in clinical trials and case series to
51 52 53 54 55 56 57 58 59
Q3
N C
49 50
U
47 48
O R
44
⁎ Corresponding author at: The National Aspergillosis Centre, 2nd Floor, Education and Research Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Manchester M23 9LT, UK. E-mail address:
[email protected] (A. Otu).
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
evaluate the efficacy of oral and parenteral antifungals [6–11]and in documentation of disease recurrence [5,12–15]. Nevertheless, there are no consensus definitions on what constitutes disease relapse in CPA. The optimal duration of treatment in CPA is also not known, and it is thought that treatment for only 6 months may be associated with recurrence [12]. Recent guidance suggests extending the course to at least 9 months, and considering long-term treatment [1]in an effort to prevent recurrence. Our practice is to continue antifungal treatment for longer than 1 year, if tolerated, especially in patients with extensive disease. However, prolonged treatment is often associated with high cost and toxic side effects. Identifying patients at low risk of relapse could allow earlier treatment discontinuation. In this study, we aim to identify risk factors for disease relapse following cessation of antifungal therapy in CPA.
60 61
2. Materials and methods
74
2.1. Patients
75
62 63 64 65 66 67 68 69 70 71 72 73
This audit involved retrospective review of data of patients with 76 CPA at the National Aspergillosis Centre (NAC), Manchester, UK. Pa- 77 tients on antifungal treatment for whom therapy was discontinued 78
https://doi.org/10.1016/j.clinpr.2020.100015 2590-1702/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015
Collected data for each patient included: 1) Baseline information: age, sex, key underlying pulmonary and systemic conditions, radiological findings at the time of discontinuation of therapy; 2) type and duration of prior antifungal therapy; 3) reason for discontinuation of antifungal therapy (intolerance, therapy failure, resistance, patient preference); 4) Relapse, as defined below, within 12 months of stopping treatment; and 5) death. The drug information (date of discontinuation, dose, and reason for discontinuation), pertinent clinical information, Aspergillus serology, sputum microbiology (microscopy, PCR, galactomannan and culture), radiographic findings and antifungal treatment information were extracted from the patients' notes.
86 87
92 93 94 95 96 97 98 99 100 101
2.3. Definitions
103 104
119 120
Relapse was defined as a deterioration in two of the following parameters: clinical, radiological, serological, or sputum microbiological markers of CPA activity. Clinical deterioration was any deterioration in systemic or respiratory symptoms, as reported by the patient and documented in the patient's notes. Radiological deterioration was defined as a worsening of respiratory imaging, either chest X-ray or chest CT scan, according to the reporting radiologist. Clinical and radiological deterioration should not have been attributable to other disease processes, notably concurrent pulmonary infection (e.g. bacterial super-infection or non-tuberculous mycobacterial infection), overt deterioration in underlying disease (e.g. sarcoidosis, rheumatoid arthritis or lung cancer) or toxicity of non-antifungal drugs. Serological deterioration was defined as any increase in Aspergillus IgG. Microbiological deterioration was defined as a new positive culture of Aspergillus from respiratory secretions or a positive Aspergillus PCR or galactomannan, deemed in the opinion of the treating physician to represent a significant result. The clinical decision of the treating physician to re-institute antifungal therapy was used as a surrogate marker of relapse.
121
2.4. Statistical analysis
122 123
Results were presented in terms of means, ranges and standard deviations for continuous data and medians and ranges for non-normally distributed variables. Pearson's chi-squared tests and Fisher's exact probability tests were performed as appropriate for categorical variables to assess for associations between relapse, radiological and clinical (co-morbidities), demographic characteristics, previous triazole therapy and reasons for discontinuation of treatment. Duration of therapy before discontinuation was assessed using Mann–Whitney U test and age was assessed using an independent t-test. Logistic regression analyses were performed with multiple covariates to determine independent predictors. Odds ratios and 95% confidence intervals (CIs) were recorded. Kaplan–Meier analyses and log-rank tests were used to assess the relationship between baseline variables of interest and the time to relapse for variables that had a significant difference in the rates of relapse. Statistical analyses were performed using SPSS version 23 (IBM Corp., Armonk, NY, USA). All tests were two-tailed and a p ≤ .05 was considered statistically significant.
115 116 117 118
124 125 126 127 128 129 130 131 132 133 134 135 136 137 138
C
E
R R
113 114
O
111 112
C
109 110
N
107 108
U
105 106
143
Antifungal therapy was discontinued in 102 patients during the audit period. Demographics and underlying disorders are shown in Table 1. At the time of diagnosis, 45 (44%) patients were found to have bilateral disease on lung imaging, and 76 (75%) patients presented with (an) aspergilloma(s) within the cavity(ies). Of the 76 patients with aspergillomas, 42 (55%) had multiple aspergillomas, and the remaining 34 (45%) had a single aspergilloma. The median duration of continuous triazole therapy before discontinuation of therapy was 19 (range: 1–106) months. At the time of discontinuation of therapy, 61 (60%) patients were on voriconazole, 31 (30%) on posaconazole, 8 (8%) on itraconazole and 2 (2%) patients were on isavuconazole for maintenance therapy. Two (2%) patients
144 145 146 147 148 149 150 151 152 153 154 155
Table 1 t1:1 Demographic, clinical, radiological, and antifungal therapy data of the 102 CPA patients t1:2 whose therapy was discontinued. t1:3
T
102
3. Results
F
90 91
85
O
2.2. Data collection and retrieval
83 84
As this study was a retrospective service evaluation, patient consent 140 was waived. All the principles of confidential transfer and handling of 141 patients' identifiable information were observed. 142
R O
89
81 82
139
2.5. Ethics
P
88
for at least one month between August 2009 and May 2017 were enrolled. The patients were followed for a minimum period of 4 months and a maximum of 12 months and their outcome evaluated. When less than 12-month follow-up was available, patients were censored at the time of last follow-up. All patients met previously described CPA diagnostic criteria involving a combination of characteristics: pulmonary disease lasting at least 3 months with a consistent appearance in thoracic imaging (preferably by CT), direct evidence of Aspergillus infection or an immunological response to Aspergillus spp. and exclusion of some alternative diagnoses [1,2].
Characteristics
Number (percent)
Demographics (n = 102) Male Female Age (years) (mean ± SD)
61 (60) 41 (40) 63.7 ± 11.5
Primary underlying conditions Chronic obstructive pulmonary disease Tuberculosis Non-tuberculous mycobacterial infection Allergic bronchopulmonary aspergillosis Pneumothorax Lobectomy Rheumatoid arthritis Asthma without ABPA or SAFS Sarcoidosis Asbestosis Sub-acute invasive pulmonary aspergillosis Community acquired pneumonia Severe asthma with fungal sensitisation (SAFS) None
26 (26) 21 (21) 9 (9) 8 (8) 8 (8) 7 (7) 7 (7) 5 (5) 3 (3) 2 (2) 2 (2) 1 (1) 1 (1) 2 (2)
Previous antifungal (prior to discontinuation) Itraconazole/102 Voriconazole/102 Posaconazole/102 Isavuconazole /102
75 (75) 92 (92) 35 (35) 2 (2)
Reasons for discontinuation (n = 102) Adverse events Resistance Resistance and adverse events Clinical failure Clinical stability
71 (71) 20 (20) 5 (5) 5 (5) 1 (1)
D
79 80
F. Bongomin et al. / Clinical Infection in Practice xxx (xxxx) xxx
E
2
Re-commencement of antifungal therapy over 12 months (n = 102) No 59 (58) Yes 43 (42) Antifungals re-commenced (n = 43) Itraconazole Voriconazole Posaconazole Isavuconazole I.V antifungals
2 (5) 2 (5) 26 (60) 8 (19) 5 (12)
Relapse criteria (n = 102) Clinical Radiological Serological Microbiological ≥2 of the above criteria
34 (33) 12 (12) 9 (9) 6 (6) 21 (21)
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015
t1:4 t1:5 t1:6 t1:7 t1:8 t1:9 t1:10 t1:11 t1:12 t1:13 t1:14 t1:15 t1:16 t1:17 t1:18 t1:19 t1:20 t1:21 t1:22 t1:23 t1:24 t1:25 t1:26 t1:27 t1:28 t1:29 t1:30 t1:31 t1:32 t1:33 t1:34 t1:35 t1:36 t1:37 t1:38 t1:39 t1:40 t1:41 t1:42 t1:43 t1:44 t1:45 t1:46 t1:47 t1:48 t1:49 t1:50 t1:51 t1:52 t1:53 t1:54 t1:55
F. Bongomin et al. / Clinical Infection in Practice xxx (xxxx) xxx
171 172 173 174
t2:1 t2:2
Table 2 Univariate analysis for risk factors for relapse of chronic pulmonary aspergillosis.
t2:3
Parameter
Total (n = 102)
t2:4 t2:5 t2:6 t2:7 t2:8 t2:9 t2:10 t2:11 t2:12
Age, median (range) Male Female Chronic obstructive pulmonary disease Tuberculosis Non-tuberculous mycobacterial infection Allergic bronchopulmonary aspergillosis Pneumothorax Rheumatoid arthritis Lobectomy Asthma without ABPA or SAFS Sarcoidosis Sub-acute invasive pulmonary aspergillosis Asbestosis Severe asthma with fungal sensitisation Community acquired pneumonia No underlying pulmonary disorder Bilateral CPA disease Unilateral CPA disease No aspergilloma Aspergilloma Single aspergilloma Multiple aspergilloma Duration of therapy before discontinuation, median (range) (months)
65 (33–91) 61 (60) 41(21) 26 (26)
65 (35–91) 48 (79) 33 (81) 21 (81)
21 (21) 9 (9)
19 (91) 6 (67)
2 (10) 3 (33)
8 (8)
7 (88)
1 (13)
8 (8) 7 (7) 7 (7) 5 (5)
5 (63) 7 (100) 5 (71) 3 (60)
3 (38) 0 (0) 2 (29) 2 (40)
3 (3) 2 (2)
2 (67) 2 (100)
1 (33) 0 (0)
2 (2) 1 (1)
0 (0) 1 (100)
t2:23 t2:24 t2:25 t2:26 t2:27 t2:28 t2:29 t2:30 t2:31 t2:32 t2:33 t2:34 t2:35 t2:36 t2:37 t2:38 t2:39 t2:40 t2:41 t2:42 t2:43 t2:44 t2:45 t2:46 t2:47
1 (1) 2 (2)
48 (51) 54 (49) 26 (31) 76 (69) 33 (43) 43 (57) 19 (1–106)
Relapse (n = 21)
p-Value
63 (33–83) 0.46 13 (21) 0.83 8 (20) 5 (19) 0.38
4. Discussion
210
E
2 (100) 0 (0)
0 (0)
1 (100)
1 (1)
1 (5)
33 (69) 15 (31) 48 (89) 6 (11) 24 (92) 2 (8) 57 (75) 19 (25) 27 (82) 6 (18) 30 (70) 13 (30) 21.3 (1–106) 15.8 (2–90)
Therapy prior to discontinuation Itraconazole 8 (8) Voriconazole 61 (60) Posaconazole 31 (30) Isavuconazole 2 (2) Reason for discontinuation of therapy Adverse events 71 (70) Triazole resistance 20 (20) Adverse events and triazole 5 (5) resistance Clinical failure 5 (5) Clinical stability 1 (1)
0.01⁎⁎ 0.06⁎ 0.23 0.35
⁎ Close to statistical significance ⁎⁎ Statistically significant.
8 (100) 47 (77) 25 (81) 1 (50)
0 (0) 14 (23) 6 (19) 1 (50)
0.28
53 (75) 18 (90) 4 (80)
18 (25) 2 (10) 1 (20)
0.48
5 (100) 1 (100)
0 (0) 0 (0)
177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209
Recurrence is well known to occur in CPA, but little studied. For this 211 reason, antifungal treatment tends to be prolonged and often long-term 212 or indefinite. Knowing which patients are at low risk of relapse will 213
R
O R
t2:22
N C
t2:17 t2:18 t2:19 t2:20 t2:21
Non-relapse (n = 81)
U
t2:13 t2:14 t2:15 t2:16
F
169 170
O
167 168
R O
165 166
P
163 164
175 176
D
162
groups are summarised in Table 2. Patients with bilateral disease and patients with one or more aspergillomas were more likely to relapse on univariate analysis. Age, sex, underlying pulmonary disorder, duration of previous triazole antifungal therapy, reasons for discontinuation of therapy and presence of a single or multiple aspergilloma were not associated with relapse. In a multivariable logistic regression analysis including bilateral/unilateral CPA disease and presence of aspergilloma, bilateral CPA disease was the only independent risk factor for relapse (Odds ratio (OR): 3.0; 95% confidence interval (CI): 1.0–8.8; p = .044). Presence of an aspergilloma was not a significant risk factor for relapse (OR: 2.9: 95% CI: 0.6–14.0; p = .189) on multivariate analysis. Overall, 8/21 (38%) patients had early relapse (relapses occurred before or at 6 months from the time of discontinuation of therapy). All 6 patients with unilateral CPA disease who relapsed, had late relapse. In contrast, 53% (8/15) of the patients with bilateral CPA disease had early relapse (Fig. 1). There was no difference in the time to relapse for patients with or without intracavitary aspergilloma (Fig. 2). For patients with unilateral disease, there was no difference in the median duration of continuous prior triazole therapy between relapse and non-relapse patient groups i.e. 16.7 (8–90) months vs. 20.0 (2– 106) months respectively (U = 141, p = 1.000). For patients with bilateral disease, the median duration of therapy was longer for the nonrelapse compared to the relapse patients i.e. 22.8 (1–92) months vs. 15.8 (2–79) months (Fig. 3). This difference was however not statistically significant (U = 212.5, p = .53). The overall survival was 96% (98 of 102) among this cohort. Of the 4 deaths, 3 (75%) patients were male. All patients died within the first 2 months following discontinuation of therapy. Three patients had progressive respiratory symptoms (clinical failure) but did not meet relapse criteria. The 4th patient was an 80-year-old with bilateral CPA disease, COPD with progressive respiratory symptoms (clinical failure) and worsening radiological features (CPA relapse) who died 2 months after discontinuation of therapy.
E
160 161
T
158 159
had been treated with all four azoles, 26 (26%) patients with 3 agents, 41 (40%) patients with 2 agents, and 33 (32%) patients had been treated with only one antifungal agent. The reasons for discontinuation of therapy are listed in Table 1. Of the 102 patients, 59 (58%) remained off therapy for the whole 12month follow-up period. Of the remaining 43 (42%) patients whose therapies were re-commenced, 34 (33%) had significant clinical deterioration, 12 (12%) patients had worsening radiological parameters, 9 (9%) patients had serological deterioration, and 6 (6%) patients had mycological relapse. Twenty-one (21%) patients met our definition of relapse, 31% of those with bilateral and 11% of those with unilateral disease (Table 2). Posaconazole was commenced in 26 of the 43 patients (60%), isavuconazole in 8 (19%) patients, voriconazole and itraconazole in 2 (5%) each, and 5 (12%) were initiated on short-course intermittent intravenous antifungal agents (Table 1). The median duration patients were off therapy before re-commencement of therapy was 4 (range: 1–11) months. The demographic, clinical, radiological characteristics and antifungal therapy data of the 102 patients stratified to relapse and non-relapse
C
156 157
3
Fig. 1. Time to relapse of CPA in patients with unilateral and bilateral disease. Patients with bilateral disease were more likely to relapse than patients with unilateral disease; moreover, patients with bilateral disease appeared to relapse earlier (log rank p = .014).
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015
F. Bongomin et al. / Clinical Infection in Practice xxx (xxxx) xxx
rate (14 out of 39), after a median duration of treatment more than 2 years [5]. Relapse can even occur following surgical resection of CPA. In a retrospective survey 30 patients who underwent surgery for CPA in our centre, relapse was noted in 8 patients (26%) [14]. Relapse after surgery carries a poor prognosis [14]. There is no consensus definition for relapse in CPA. Different studies employ different criteria to define relapse. The difficulty arises from the frequent presence of comorbidities including bacterial superinfection and concomitant non-tuberculous mycobacterial infection to which these patients are susceptible. In addition, deterioration of the underlying pulmonary condition (e.g. COPD) often plays a role. A variety of criteria were used in the aforementioned studies. In real-life clinical practice, a combination of clinical, radiological and microbiological parameters often leads the clinician to suspect a recurrence. In our study, restarting antifungal therapy was most often associated with a clinical deterioration only, without evidence of radiological, microbiological or serological relapse. Using our definition of relapse, about half of the patients who were restarted on antifungal therapy did not fulfil this definition of relapse of CPA. To date, only one study has focused on defining risk factors for recurrence in CPA [5]. In a retrospective study of patients with CPA who were mainly treated with itraconazole, presence of disease in more than one lobe on CT scan, younger age and longer duration of treatment to achieve remission were associated with a higher risk of relapse. Multilobar disease appeared to be the strongest risk factor. In our study, we used bilateral disease as a marker of extent of disease, as more than half of patients had disease involving both lungs. In addition, we found an association between the presence of aspergilloma and recurrence. Both bilateral disease and presence of aspergillomas are established markers of higher CPA burden. Regarding duration of treatment, patients with bilateral disease who did not relapse were treated for almost 2 years, whereas duration of treatment did not affect relapse rate in unilateral disease. Therefore, treatment duration of 2 years may be recommended for patients with bilateral CPA, whereas a shorter course, e.g. 6–18 months may be adequate for most patients with
P
D
T
C
E
224 225
R R
222 223
O
220 221
C
218 219
N
216 217
allow for earlier discontinuation of antifungal treatment, thereby limiting antifungal toxicity, cost and emergence of resistance. Our study showed that bilateral disease and, to a lesser extent, presence of an aspergilloma are the main risk factors for relapse. Recurrence rates in CPA vary from 17% to 38% in various studies. In a prospective trial of itraconazole for 6 months vs. placebo, 5 of 13 (38%) patients who had initially responded had a relapse after a median of 11 months off treatment [12]. A prospective trial of voriconazole, in which the mean duration of treatment was 8.3 months, resulted in radiological or mycological relapse in 3/18 (17%) of patients. Finally, a retrospective study of patients who were mainly treated with itraconazole showed a 36% recurrence
U
214 215
E
Fig. 2. Time to relapse of CPA in patients with or without intracavitary aspergilloma. There is no statistically significant difference in the time to relapse for patients with or without intracavitary aspergilloma (log rank p = .180).
R O
O
F
4
Fig. 3. Duration of prior triazole therapy. Median duration of therapy in patients with CPA who relapsed vs. those who did not. Unilateral disease (A): 16.7 (8–90) months in the relapse group vs. 20.0 (2–106) months in the non-relapse group (U = 141, p N .99) and bilateral disease (B) 22.8 (1–92) months for non-relapse vs. 15.8 (2–79) months for relapse (U = 212.5, p = .53).
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015
226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260
F. Bongomin et al. / Clinical Infection in Practice xxx (xxxx) xxx
270 271 272 273 274 275 276 277 278 279
283
19 Acknowledgements
285 286 287
This work was presented in part at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, 2017) held in Vienna, Austria.
288
Funding
289 290
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
291
Declaration of competing interest
292
Dr. Denning and family hold Founder shares in F2G Ltd., a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Astellas, Sigma Tau, Basilea, Scynexis, Cidara, Biosergen, Quintiles, Pulmatrix, Pulmocide and Zambon. In the last 3 years, he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee. FB, AO, CH, FP and CK: None to declare.
301 302
C
E R
O R
299 300
N C
297 298
U
295 296
T
284
293 294
F
268 269
304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364
D
267
1. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47: 45–68 Available at http://www.ncbi.nlm.nih.gov/pubmed/26699723. 2. Patterson TF, Iii RT, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63:1–60 Available at http://www.ncbi.nlm.nih.gov/pubmed/ 27365388. 3. Verweij PE, Chowdhary A, Melchers WJG, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2016;62:362–8 Available at https://doi.org/10.1093/cid/civ885. 4. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006;52:e133–7 Available at http:// www.ncbi.nlm.nih.gov/pubmed/16427702. 5. Koyama K, Ohshima N, Suzuki J, et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014;20:375–9 Available at https://doi.org/10.1016/j.jiac.2014.02.003. 6. Cucchetto G, Cazzadori a, Conti M, Cascio GL, Braggio P, Concia E. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series. Infection 2015;43:277–86. 7. Uffredi ML, Mangiapan G, Cadranel J, Kac G. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003;22:457–62. 8. Godet C, Laurent F, Bergeron A, et al. CT imaging assessment of response to treatment in chronic pulmonary aspergillosis. Chest 2016;150:139–47 Available at http:// linkinghub.elsevier.com/retrieve/pii/S0012369216012599. 9. Kohno S, Izumikawa K, Kakeya H, et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011;49:688–93 Available at http://www.ncbi.nlm.nih.gov/ pubmed/21355713. 10. Ohba H, Miwa S, Shirai M, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012;106:724–9 Available at http://www.ncbi.nlm. nih.gov/pubmed/22349065. 11. Izumikawa K, Ohtsu Y, Kawabata M, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007;45:273–8. 12. Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013;56:559–70. 13. Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012;31: 3231–9 Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3479377&tool=pmcentrez&rendertype=abstract. 14. Farid S, Mohamed S, Devbhandari M, et al. Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence—a national centre's experience. J Cardiothorac Surg 2013;8:180 Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3750592&tool= pmcentrez&rendertype=abstract. 15. Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg 2009;138:820–5 Available at https://doi.org/10.1016/j.jtcvs.2009.01.019. 16. Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW, Rodrigues F. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008;197:618–21. 17. Smith NLD, Hankinson J, Simpson A, Bowyer P, Denning DW. A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. Clin Microbiol Infect 2014;20:O480–8 Available at https://doi.org/10.1111/14690691.12473. 18. Smith NLD, Hankinson J, Simpson A, Denning DW, Bowyer P. Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. Clin Microbiol Infect 2014;20:O960–8 Available at https://doi.org/10.1111/1469-0691.12643. 19. Bongomin F, Harris C, Foden P, Kosmidis C, Denning DW. Innate and adaptive immune defects in chronic pulmonary aspergillosis. J Fungi 2017;3:26 Available at: http://www.mdpi.com/2309-608X/3/2/26.
O
Uncited reference
265 266
303 Q7
R O
282 Q6
263 264 Q5
References
P
280 281
low-burden disease. Genetic polymorphisms [16–18] and subtle immunodeficiency states have been associated with the development of CPA. Further research is required to determine if there is a link between these conditions constituting risks for relapse of CPA. Our study has several limitations. First, our definition of relapse did not include radiological confirmation in every case, as in the study by Koyama and colleagues [5]. However, in patients with CPA, radiological deterioration may lag behind clinical relapse. Second, it was a retrospective study that was characterised by the typical methodological limitations. Third, our cohort had variable durations of treatment, and antifungals were stopped mainly because of side effects or resistance development, and not because of achieving remission of disease. Although the median duration of continuous triazole therapy before discontinuation of therapy was 19 months, some patients may have actually had persistent disease and not a recurrence. This could have led to an overestimate of the rate of relapse. In conclusion, bilateral disease is a risk factor for relapse after treatment discontinuation in CPA. A longer duration of treatment, e.g. 24 months, may be associated with a lower rate of relapse in extensive CPA, whereas more limited disease may respond to shorter courses.
E
261 262
5
Please cite this article as: F. Bongomin, A. Otu, C. Harris, et al., Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal ther..., Clinical Infection in Practice, https://doi.org/10.1016/j.clinpr.2020.100015